p.90 抽出テキスト

atherosclerosis: a secondary outcome of a randomized clinical trial. JAMA Netw Open 2021;4:e2121683. https://doi.org/10.1001/jamanetworkopen.2021.21683 268. Muiesan ML, Salvetti M, Monteduro C, Bonzi B, Paini A, Viola S, et al. Left ventricular concentric geometry during treatment adversely affects cardiovascular prognosis in hypertensive patients. Hypertension 2004;43:731–8. https://doi.org/10.1161/01.HYP. 0000121223.44837.de 269. Guerin AP, Blacher J, Pannier B, Marchais SJ, Safar ME, London GM, et al. Impact of aortic stiffness attenuation on survival of patients in end-stage renal failure. Circulation 2001;103:987–92. https://doi.org/10.1161/01.cir.103.7.987 270. Cardoso CRL, Salles GF. Prognostic value of changes in aortic stiffness for cardiovascular outcomes and mortality in resistant hypertension: a cohort study. Hypertension 2022;79:447–56. https://doi.org/10.1161/hypertensionaha.121.18498 271. Laurent S, Chatellier G, Azizi M, Calvet D, Choukroun G, Danchin N, et al. SPARTE study: normalization of arterial stiffness and cardiovascular events in patients with hypertension at medium to very high risk. Hypertension 2021;78:983–95. https://doi. org/10.1161/hypertensionaha.121.17579 272. Levin A, Stevens PE, Bilous RW, Coresh J, De Francisco ALM, De Jong PE, et al. Summary of recommendation statements. Kidney Int Suppl (2011) 2013;3:5–14. https://doi.org/10.1038/kisup.2012.77 273. Matsushita K, Coresh J, Sang Y, Chalmers J, Fox C, Guallar E, et al. Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis of individual participant data. Lancet Diabetes Endocrinol 2015;3: 514–25. https://doi.org/10.1016/s2213-8587(15)00040-6 274. Cheung AK, Rahman M, Reboussin DM, Craven TE, Greene T, Kimmel PL, et al. Effects of intensive BP control in CKD. J Am Soc Nephrol 2017;28:2812–23. https://doi.org/10. 1681/asn.2017020148 275. Malhotra R, Nguyen HA, Benavente O, Mete M, Howard BV, Mant J, et al. Association between more intensive vs less intensive blood pressure lowering and risk of mortality in chronic kidney disease stages 3 to 5: a systematic review and meta-analysis. JAMA Intern Med 2017;177:1498–505. https://doi.org/10.1001/jamainternmed.2017.4377 276. Stevens PE, Levin A. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med 2013;158:825–30. https://doi.org/10.7326/0003-4819-158- 11-201306040-00007 277. Aboyans V, Ricco JB, Bartelink MEL, Björck M, Brodmann M, Cohnert T, et al. 2017 ESC Guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European Society for Vascular Surgery (ESVS): document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteriesEndorsed by: the European Stroke Organization (ESO) The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J 2018;39:763–816. https://doi.org/10.1093/eurheartj/ehx095 278. Iribarren C, Round AD, Lu M, Okin PM, McNulty EJ. Cohort study of ECG left ventricular hypertrophy trajectories: ethnic disparities, associations with cardiovascular outcomes, and clinical utility. J Am Heart Assoc 2017;6:e004954. https://doi.org/10. 1161/jaha.116.004954 279. Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Dahlöf B. Baseline characteristics in relation to electrocardiographic left ventricular hypertrophy in hypertensive patients: the Losartan Intervention For Endpoint reduction (LIFE) in hypertension study. Hypertension 2000;36:766–73. https://doi.org/10.1161/01.hyp.36.5.766 280. Okin PM, Oikarinen L, Viitasalo M, Toivonen L, Kjeldsen SE, Nieminen MS, et al. Prognostic value of changes in the electrocardiographic strain pattern during antihypertensive treatment: the Losartan Intervention for End-point reduction in hypertension study (LIFE). Circulation 2009;119:1883–91. https://doi.org/10.1161/ circulationaha.108.812313 281. Lehtonen AO, Puukka P, Varis J, Porthan K, Tikkanen JT, Nieminen MS, et al. Prevalence and prognosis of ECG abnormalities in normotensive and hypertensive individuals. J Hypertens 2016;34:959–66. https://doi.org/10.1097/hjh.0000000000000882 282. Pewsner D, Jüni P, Egger M, Battaglia M, Sundström J, Bachmann LM. Accuracy of electrocardiography in diagnosis of left ventricular hypertrophy in arterial hypertension: systematic review. BMJ 2007;335:711. https://doi.org/10.1136/bmj.39276.636354.AE 283. Kuznetsova T, Thijs L, Knez J, Cauwenberghs N, Petit T, Gu Y-M. Longitudinal changes in left ventricular diastolic function in a general population. Circ Cardiovasc Imaging 2015;8:e002882. https://doi.org/10.1161/circimaging.114.002882 284. Zhao L, Zierath R, Claggett B, Dorbala P, Matsushita K, Kitzman D. Longitudinal changes in left ventricular diastolic function in late life: the ARIC study. JACC Cardiovasc Imaging 2023;16:1133–45. https://doi.org/10.1016/j.jcmg.2023.02.022 285. Redfield MM, Jacobsen SJ, Burnett JC Jr, Mahoney DW, Bailey KR, Rodeheffer RJ. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 2003;289:194–202. https://doi.org/10. 1001/jama.289.2.194 286. Sundström J, Lind L, Arnlöv J, Zethelius B, Andrén B, Lithell HO. Echocardiographic and electrocardiographic diagnoses of left ventricular hypertrophy predict mortality independently of each other in a population of elderly men. Circulation 2001;103:2346–51. https://doi.org/10.1161/01.cir.103.19.2346 287. Seko Y, Kato T, Yamaji Y, Haruna Y, Nakane E, Haruna T, et al. Discrepancy between left ventricular hypertrophy by echocardiography and electrocardiographic hypertrophy: clinical characteristics and outcomes. Open Heart 2021;8:e001765. https:// doi.org/10.1136/openhrt-2021-001765 288. Modin D, Biering-Sørensen SR, Mogelvang R, Landler N, Jensen JS, Biering-Sørensen T. Prognostic value of echocardiography in hypertensive versus nonhypertensive participants from the general population. Hypertension 2018;71:742–51. https://doi.org/10. 1161/hypertensionaha.117.10674 289. Armstrong AC, Jacobs DR Jr, Gidding SS, Colangelo LA, Gjesdal O, Lewis CE, et al. Framingham score and LV mass predict events in young adults: CARDIA study. Int J Cardiol 2014;172:350–5. https://doi.org/10.1016/j.ijcard.2014.01.003 290. Kuznetsova T, Thijs L, Knez J, Herbots L, Zhang Z, Staessen JA. Prognostic value of left ventricular diastolic dysfunction in a general population. J Am Heart Assoc 2014;3: e000789. https://doi.org/10.1161/jaha.114.000789 291. Marwick TH, Gillebert TC, Aurigemma G, et al. Recommendations on the use of echocardiography in adult hypertension: a report from the European Association of Cardiovascular Imaging (EACVI) and the American Society of Echocardiography (ASE). Eur Heart J Cardiovasc Imaging 2015;16:577–605. https://doi.org/10.1093/ehjci/ jev076 292. Douglas PS, Garcia MJ, Haines DE, Lai WW, Manning WJ, Patel AR, et al. ACCF/ASE/ AHA/ASNC/HFSA/HRS/SCAI/SCCM/SCCT/SCMR 2011 appropriate use criteria for echocardiography. A report of the American College of Cardiology Foundation appropriate use criteria task force, American Society of Echocardiography, American Heart Association, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Critical Care Medicine, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance American College of Chest Physicians. J Am Soc Echocardiogr 2011;24:229–67. https://doi.org/ 10.1016/j.echo.2010.12.008 293. van Rosendael AR, Bax AM, Smit JM, van den Hoogen IJ, Ma X, Al’Aref S, et al. Clinical risk factors and atherosclerotic plaque extent to define risk for major events in patients without obstructive coronary artery disease: the long-term coronary computed tomography angiography CONFIRM registry. Eur Heart J Cardiovasc Imaging 2020;21: 479–88. https://doi.org/10.1093/ehjci/jez322 294. Mehta A, Pandey A, Ayers CR, Khera A, Sperling LS, Szklo M, et al. Predictive value of coronary artery calcium score categories for coronary events versus strokes: impact of sex and race: MESA and DHS. Circ Cardiovasc Imaging 2020;13:e010153. https://doi. org/10.1161/circimaging.119.010153 295. Bengtsson A, Lindvall K, Norberg M, Fhärm E. Increased knowledge makes a difference! —general practitioners’ experiences of pictorial information about subclinical atherosclerosis for primary prevention: an interview study from the VIPVIZA trial. Scand J Prim Health Care 2021;39:77–84. https://doi.org/10.1080/02813432.2021.1882083 296. Ibanez B, Fernández-Ortiz A, Fernández-Friera L, García-Lunar I, Andrés V, Fuster V. Progression of early subclinical atherosclerosis (PESA) study: JACC focus seminar 7/8. J Am Coll Cardiol 2021;78:156–79. https://doi.org/10.1016/j.jacc.2021.05.011 297. Den Ruijter HM, Peters SA, Anderson TJ, Britton AR, Dekker JM, Eijkemans MJ. Common carotid intima-media thickness measurements in cardiovascular risk prediction: a meta-analysis. JAMA 2012;308:796–803. https://doi.org/10.1001/ jama.2012.9630 298. Downie LE, Hodgson LA, DSylva C, McIntosh RL, Rogers SL, Connell P, et al. Hypertensive retinopathy: comparing the Keith-Wagener-Barker to a simplified classification. J Hypertens 2013;31:960–5. https://doi.org/10.1097/HJH.0b013e32835efea3 299. Liew G, Xie J, Nguyen H, Keay L, Kamran Ikram M, McGeechan K, et al. Hypertensive retinopathy and cardiovascular disease risk: 6 population-based cohorts meta-analysis. Int J Cardiol Cardiovasc Risk Prev 2023;17:200180. https://doi.org/10.1016/j.ijcrp. 2023.200180 300. Padmanabhan S, Caulfield M, Dominiczak AF. Genetic and molecular aspects of hypertension. Circ Res 2015;116:937–59. https://doi.org/10.1161/circresaha.116.303647 301. Casey R, Neumann HPH, Maher ER. Genetic stratification of inherited and sporadic phaeochromocytoma and paraganglioma: implications for precision medicine. Hum Mol Genet 2020;29:R128–137. https://doi.org/10.1093/hmg/ddaa201 302. Rossi GP, Ceolotto G, Caroccia B, Lenzini L. Genetic screening in arterial hypertension. Nat Rev Endocrinol 2017;13:289–98. https://doi.org/10.1038/nrendo.2016.196 303. Cascón A, Calsina B, Monteagudo M, Mellid S, Díaz-Talavera A, Currás-Freixes M, et al. Genetic bases of pheochromocytoma and paraganglioma. J Mol Endocrinol 2023;70: e220167. https://doi.org/10.1530/jme-22-0167 304. Staessen JA, Wang J, Bianchi G, Birkenhäger WH. Essential hypertension. Lancet 2003; 361:1629–41. https://doi.org/10.1016/s0140-6736(03)13302-8 305. Lenders JW, Duh QY, Eisenhofer G, Gimenez-Roqueplo A-P, Grebe SKG, Murad MH, et al. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2014;99:1915–42. https://doi.org/10. 1210/jc.2014-1498 306. Poulter NR, Prabhakaran D, Caulfield M. Hypertension. Lancet 2015;386:801–12. https://doi.org/10.1016/s0140-6736(14)61468-9 307. Mills KT, Bundy JD, Kelly TN, Reed JE, Kearney PM, Reynolds K, et al. Global disparities of hypertension prevalence and control: a systematic analysis of population-based

ESC Guidelines                                                                                                                                                                                          4001

Downloaded from academic.oup.com/eurheartj/article/45/38/3912/7741010 by guest on 07 October 2026